Aces Diagnostics Partners to Enhance LymeSeek™ Test Development
Aces Diagnostics Inc., a company with a focus on innovative diagnostics for Lyme disease, has announced new developments that hold great promise for the future of LymeSeek™. Through partnerships with Protavio and Repado, Aces is taking significant steps toward making its pioneering LymeSeek™ test commercially available.
Understanding LymeSeek™
LymeSeek™ is a groundbreaking diagnostic tool that utilizes a single-blood-draw process, employing advanced multiplexed immunoassay techniques along with a proprietary machine-learning algorithm to deliver over 90% accuracy in detecting Lyme disease at any stage. This novel approach marks a significant improvement compared to current testing methods, particularly in identifying early-stage infections that conventional tests often overlook.
Addressing a Global Health Concern
Lyme disease is increasingly recognized as a significant public health issue, with an estimated prevalence of 14.5% globally. In the U.S., the Centers for Disease Control and Prevention (CDC) statistics highlight around 476,000 new cases each year, positioning Lyme disease as one of the prevalent infectious diseases within the country. These stats underscore the urgent need for reliable testing solutions.
Strategic Collaborations to Meet Standards
Aces Diagnostics is committed to meeting rigorous FDA and ISO 13485 standards, necessitating collaboration with top professionals in the field. Protavio, known for its expertise in multiplex proteomics and based in Athens, Greece, is taking the lead in developing the IVD-grade test kit for LymeSeek™, ensuring quality design and production that adhere to strict regulations.
Advancing Software Development
Complementing the test kit development, Repado, a certified software firm specializing in life sciences and healthcare technologies, is tasked with creating the LymeSeek™ Analysis software. This platform integrates Aces’ advanced machine-learning algorithm to produce final diagnostic reports that maintain high accuracy and objectivity.
CEO Insights on Long-Term Goals
CEO Tammy Crawford expressed her firm belief in the mission behind LymeSeek™. She stated, "The development of LymeSeek is a mission-driven effort for our entire team, and these strategic partnerships are instrumental to its success." According to her, the combination of Protavio's expertise in assay development and Repado's advanced software capabilities is essential for creating a reliable and scalable diagnostic tool. By improving early diagnostic capabilities, LymeSeek™ aims to significantly reduce long-term health complications for patients.
A Collaborative Approach to Innovation
Through the combined resources of Aces Diagnostics, Protavio, and Repado, the trio aims to deliver the first clinically accurate in-vitro diagnostic that can effectively identify all stages of Lyme disease. The LymeSeek™ initiative embodies an extensive collaboration, driving to fill the existing gaps in diagnostics that leave many patients without timely answers.
Conclusion: Aces Diagnostics' Vision
For those eager to learn about Aces Diagnostics' innovative efforts in Lyme disease testing, further information is readily available on their official website. By focusing on strategic partnerships and innovative research, Aces Diagnostics is committed to reshaping the landscape of Lyme disease diagnostics.
Frequently Asked Questions
What is LymeSeek™?
LymeSeek™ is a novel diagnostic test designed to accurately detect Lyme disease through a single blood draw, utilizing advanced technology to enhance accuracy at all infection stages.
Why is Lyme disease testing important?
Early and reliable testing for Lyme disease is crucial as it can lead to prompt treatment and reduce the risk of long-term health complications associated with late diagnosis.
Who are Aces Diagnostics' partners in developing LymeSeek™?
Aces Diagnostics collaborates with Protavio for assay development and Repado for creating the diagnostic analysis software.
What standards are Aces Diagnostics following?
Aces Diagnostics is ensuring their LymeSeek™ test meets the stringent regulations set by the FDA and ISO 13485 for quality assurance and compliance.
How does LymeSeek™ improve upon current testing methods?
LymeSeek™ offers over 90% accuracy compared to traditional tests, significantly enhancing the ability to detect early-stage Lyme disease infections that are often missed.
